Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2018/2852398 http://scihub22266oqcxt.onion/10.1155/2018/2852398 C5822931!5822931 !29577044     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29577044 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29577044 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Diabetes+Res 2018 ; 2018 (ä): 2852398 Nephropedia Template TP {{tp|p=29577044 |t=2018. Tubulointerstitial Biomarkers for Diabetic Nephropathy |pdf=|usr=}}{{29577044 }} gab.com Text Tubulointerstitial Biomarkers for Diabetic Nephropathy JO: J Diabetes Res http://www.kidney.de/pget.php?&tw=1&pmid=29577044 #FOAvip Patients with diabetic nephropathy have a higher risk of mortality, mostly from cardiovascular complications. Standard biomarkers including serum creatinine, estimated glomerular filtration rate, and albuminuria are imprecise, do not directly measure renal tissue injury, and are relatively insensitive to small changes in renal function. Thus, availability of novel biomarkers that are sensitive, specific, and precise as well as able to detect kidney injury and predict clinically significant outcomes would be widely useful in diabetic nephropathy. Novel biomarkers of the processes that induce tubulointerstitial changes may ultimately prove to better predict renal progression and prognosis in type 2 diabetes. Recently, certain biomarkers, which were initially identified in acute kidney injury, also have been reported to confer value in evaluating patients with chronic kidney disease. Biomarkers such as cystatin C, kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), angiotensinogen, periostin, and monocyte chemoattractant protein-1 (MCP-1) reflect tubular injury. In this article, we focused on the potential applications of these biomarkers in diabetic nephropathy. Twit Text FOAVip Tubulointerstitial Biomarkers for Diabetic Nephropathy ????J Diabetes Res http://www.kidney.de/pget.php?&tw=1&pmid=29577044 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29577044 #FOAvip English Wikipedia <ref>{{Cite pmid|29577044 }}</ref> Tubulointerstitial Biomarkers for Diabetic Nephropathy #MMPMID29577044 Satirapoj B J Diabetes Res 2018[]; 2018 (ä): 2852398 PMID29577044 show ga Patients with diabetic nephropathy have a higher risk of mortality, mostly from cardiovascular complications. Standard biomarkers including serum creatinine, estimated glomerular filtration rate, and albuminuria are imprecise, do not directly measure renal tissue injury, and are relatively insensitive to small changes in renal function. Thus, availability of novel biomarkers that are sensitive, specific, and precise as well as able to detect kidney injury and predict clinically significant outcomes would be widely useful in diabetic nephropathy. Novel biomarkers of the processes that induce tubulointerstitial changes may ultimately prove to better predict renal progression and prognosis in type 2 diabetes. Recently, certain biomarkers, which were initially identified in acute kidney injury, also have been reported to confer value in evaluating patients with chronic kidney disease. Biomarkers such as cystatin C, kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), angiotensinogen, periostin, and monocyte chemoattractant protein-1 (MCP-1) reflect tubular injury. In this article, we focused on the potential applications of these biomarkers in diabetic nephropathy. |Angiotensinogen/blood [MESH] |Biomarkers/*blood [MESH] |Chemokine CCL2/blood [MESH] |Cystatin C/blood [MESH] |Diabetic Nephropathies/blood/*diagnosis [MESH] |Hepatitis A Virus Cellular Receptor 1/blood [MESH] |Humans [MESH]Tubulointerstitial Biomarkers for Diabetic Nephropathy (epmc).pdf DeepDyve Pubget Overpricing